Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies

Molecules, Год журнала: 2024, Номер 29(23), С. 5564 - 5564

Опубликована: Ноя. 25, 2024

Amidst the ongoing global challenge of SARS-CoV-2 pandemic, quest for effective antiviral medications remains paramount. This comprehensive review delves into dynamic landscape FDA-approved repurposed COVID-19, categorized as and non-antiviral agents. Our focus extends beyond conventional narratives, encompassing vaccination targets, repurposing efficacy, clinical studies, innovative treatment modalities, future outlooks. Unveiling genomic intricacies variants, including WHO-designated Omicron variant, we explore diverse categories such fusion inhibitors, protease transcription neuraminidase nucleoside reverse transcriptase, interventions like importin α/β1-mediated nuclear import neutralizing antibodies, convalescent plasma. Notably, Molnupiravir emerges a pivotal player, now licensed in UK. offers fresh perspective on historical evolution COVID-19 therapeutics, from endeavors to latest developments oral anti-SARS-CoV-2 treatments, ushering new era hope battle against pandemic.

Язык: Английский

---

Intra-host variability of SARS-CoV-2: Patterns, causes and impact on COVID-19

Virology, Год журнала: 2024, Номер 603, С. 110366 - 110366

Опубликована: Дек. 22, 2024

Язык: Английский

---